Companies in #Acute Myeloid Leukemia
Found 2 companies operating in this sector.
IN8bio is a New York-based clinical-stage biopharmaceutical company developing genetically modified gamma-delta (γδ) T cell therapies and γδ T cell engagers (TCEs) for solid and hematologic malignancies. Lead programs include INB-100 (donor-derived γδ T cells for leukemia patients undergoing haploidentical transplant), INB-200 and INB-400 (autologous γδ T cells for glioblastoma), and INB-619, a CD19-targeting γδ T cell engager advancing into IND-enabling studies. The company reported $18.0M in cash at June 30, 2026. Co-founded in 2016 by CEO William Ho and scientific founder Dr. Lawrence Lamb.
Rigel Pharmaceuticals is a commercial-stage biotechnology company focused on hematologic disorders and cancer, marketing TAVALISSE (fostamatinib) for chronic immune thrombocytopenia, REZLIDHIA (olutasidenib) for relapsed or refractory AML with an IDH1 mutation, and GAVRETO (pralsetinib) for RET fusion-positive cancers.